The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
PharmVar GeneFocus: CYP2B6
Open accessAbstract
The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP2B6 gene. Genetic variation within the CYP2B6 gene locus impacts the metabolism or bioactivation of clinically important drugs. Of particular importance are efficacy and safety concerns regarding: efavirenz, which is used for the treatment of HIV type‐1 infection; methadone, a mainstay in the treatment of opioid use disorder and as an analgesic; ketamine, used as an antidepressant and analgesic; and bupropion, which is prescribed to treat depression and for smoking cessation. This GeneFocus provides a comprehensive overview and summary of CYP2B6 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“Until the end of 1990s, CYP2B6 was thought to be an insignificant component of the hepatic P450 system, as earlier studies reported very low or undetectable CYP2B6 protein expression in a significant proportion of human liver tissues, in part due to a lack of reliable antibodies.(7) However, after specific antibodies…”
Machiela, M. J., & Chanock, S. J. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv402 · Cited by 2,069
Browning, B. L., & Browning, S. R. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.01.005 · Cited by 1,640
Human cytochromes P450 in health and disease
Nebert, D. W., Wikvall, K., & Miller, W. L. (2013) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0431 · Cited by 505
Altered methadone pharmacokinetics in methadone-maintained pregnant women.
Pond, S. M., Kreek, M. J., Tong, T. G., Raghunath, J., & Benowitz, N. L. (1985) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21130-2 · Cited by 189
Cited by
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2903 · Cited by 521
Self-citationCrews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Callaghan, J. T., Samer, C. F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2149 · Cited by 434
Self-citationPharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020) · Genes · doi:10.3390/genes11111295 · Cited by 316
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
Chen, X., Shen, F., Gonzaludo, N., Malhotra, A., Rogert, C., Taft, R. J., Bentley, D. R., & Eberle, M. A. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-00205-5 · Cited by 95
Metadata
- Authors
- Desta, Z., El‐Boraie, A., Gong, L., Somogyi, A. A., Lauschke, V. M., Dandara, C., Klein, K., Miller, N. A., Klein, T. E., Tyndale, R. F., Whirl‐Carrillo, M., & Gaedigk, A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2021-03-11
- Volume
- 110
- Issue
- 1
- Pages
- 82-97
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2976816195
- Cited by
- 234
- References
- 6
- FWCI
- 35.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.